Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

PHASE2RecruitingINTERVENTIONAL

Enrollment

145

Participants

Timeline

Start Date

October 25, 2018

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Azacitidine

Given SC or IV

DRUG

Cladribine

Given IV

DRUG

Cytarabine

Given SC

DRUG

Venetoclax

Given PO

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER